Latest News & Features
Big Pharma
A Spain-based pharmaceutical company has applied to trademark ‘Brexit’, the term coined for the UK’s potential departure from the EU. 22 June 2016
Americas
The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer. 22 June 2016
Americas
The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price. 21 June 2016
Americas
Japan-based pharmaceutical company Daiichi Sankyo has secured victory in an inter partes review against Canada-based Alethia Biotherapeutics. 20 June 2016
Americas
Business law firm Procopio has added Robert Ramos as a partner in its life sciences practice group in San Diego. 20 June 2016
Americas
Authorities in Arizona arrested 26 people, while 23 businesses were raided, in a counterfeit prescription drug operation last Wednesday. 17 June 2016
Americas
The US Court of Appeals for the Federal Circuit decided on June 14 that the two patents involved in a dispute between Biomarin Pharmaceuticals and Genzyme Therapeutic Products are unpatentable due to being obvious. 16 June 2016
Video
In a video interview that was conducted at the 2016 BIO International Convention last week, LSIPR spoke to Crawford Jones, ISS media specialist from NASA, and Michael Roberts, deputy chief scientist from partner organisation CASIS, about using space as an environment for research as well as NASA’s relationship with intellectual property. 16 June 2016
Asia
In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report. 16 June 2016
Africa
The “Global Generic Drugs Market 2016-2020” report predicts that the expiry of patents for branded drugs, worth $150 billion, will allow generic companies to prosper by 2020. 15 June 2016